Hypofractionation and Ultra-Short Radiation Protocols
Hypofractionation and ultra-short radiation regimens are reshaping cancer treatment paradigms by delivering higher doses per fraction over fewer sessions. This session explores the clinical evidence supporting hypofractionated schedules in breast, prostate, and lung cancers. Advances in stereotactic body radiotherapy (SBRT) and ultra-high dose rate (FLASH) radiotherapy will be discussed, focusing on their biological advantages and potential to reduce treatment-related toxicity. Speakers will review radiobiological principles, patient selection criteria, and implementation challenges in diverse healthcare settings. The session will also examine economic benefits, improved patient convenience, and resource optimization, particularly in low-resource regions. Hypofractionation represents a patient-centered and sustainable approach, balancing efficacy, safety, and accessibility in modern oncology practice.